What is onchocerciasis?

Onchocerciasis is a parasitic disease caused by the filarial worm Onchocerca volvulus, transmitted through the bites of Simulium black flies breeding near fast-flowing rivers. Adult worms live in subcutaneous nodules and produce millions of microfilariae that migrate throughout the body — causing intense itching, skin disease and, when they die in the eye, progressive visual loss and blindness. It affects 220 million people at risk in 31 countries — primarily in Sub-Saharan Africa.

How does onchocerciasis cause blindness?

Onchocercal blindness is caused by microfilariae (released by adult female worms in nodules) migrating to the cornea and other eye structures. When microfilariae die in the cornea, the immune reaction causes punctate keratitis → sclerosing keratitis → corneal opacification → blindness. Eye lesions are also caused in the iris, lens, choroid and optic nerve. Communities near fast-flowing rivers historically had endemic blindness — with up to 10% of adults blinded.

What is the Mectizan donation programme?

In 1987, Merck & Co. announced the donation of ivermectin (Mectizan) "for as long as needed, to as many as needed" for river blindness — the first major pharmaceutical donation for a neglected disease. This decision transformed global health partnerships. By 2022, over 4 billion treatments had been distributed. The donation extended to lymphatic filariasis in co-endemic African countries. The programme is managed through the Mectizan Donation Program (MDP) administered by Emory University.

How is onchocerciasis treated?

Ivermectin (Mectizan): taken annually — kills microfilariae and prevents progression to blindness and skin disease. Does not kill adult worms (which can live 15 years). Must be taken annually for the lifespan of adult worms. Doxycycline (anti-Wolbachia): a 4-6 week course kills Wolbachia endosymbiont bacteria essential for worm reproduction and survival — effectively sterilising and eventually killing adult worms. Moxidectin: more potent single dose than ivermectin — approved for onchocerciasis treatment.

Can onchocerciasis be eliminated in Africa?

Africa carries 99% of the global onchocerciasis burden. Elimination is challenging due to: very large population requiring treatment; co-endemicity with loiasis in Central Africa (ivermectin causes severe reactions in high-level loiasis infection — the "Loa loa problem," limiting MDA); lack of a macrofilaricide that kills adult worms rapidly; and incomplete coverage in some areas. New tools (moxidectin, anti-Wolbachia doxycycline) and expanded coverage are accelerating progress. WHO targets elimination in 12 African countries by 2030.

What is the Loa loa problem?

In parts of Central Africa (DRC, Cameroon, Nigeria), Loa loa (eye worm) is co-endemic with onchocerciasis. High-level Loa loa microfilaraemia (>30,000 mf/mL) causes severe adverse events (encephalopathy, coma) when ivermectin is given. This has excluded approximately 50 million people in co-endemic areas from standard CDTI. Solutions: LoaScope (smartphone-based point-of-care Loa loa test); test-and-treat strategies; moxidectin (safer than ivermectin in Loa co-infection).

What causes the skin disease in onchocerciasis?

Onchocercal skin disease (OSD) is caused by the immune response to dying microfilariae in the skin — causing intense pruritus (the most common manifestation), lichenification (thickened, scaly skin — "lizard skin"), depigmentation (spotty loss of melanin — "leopard skin"), and premature ageing (loss of skin elasticity). OSD causes profound disability and stigma — those with severe OSD cannot work, sleep or function normally. It is highly disabling even when blindness has not yet occurred.

How does GMJ News cover onchocerciasis?

GMJ News covers WHO NTD Roadmap onchocerciasis targets, Mectizan donation milestones, OEPA elimination success, moxidectin FDA approval and anti-Wolbachia therapy development. Onchocerciasis is part of the GMJ's NTD and neglected disease coverage.

Home › Topics › Onchocerciasis (River Blindness)

Onchocerciasis (River Blindness)

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Onchocerciasis (river blindness) — caused by the filarial worm Onchocerca volvulus transmitted by black flies (Simulium species) breeding in fast-flowing rivers — has blinded approximately 1.1 million people and visually impaired hundreds of thousands more, earning its name from communities living along affected rivers where blindness was epidemic (WHO). An estimated 220 million people remain at risk in 31 countries — predominantly in Sub-Saharan Africa. Ivermectin (Mectizan) — donated by Merck since 1987 in what became the largest drug donation programme in history — kills the microfilariae causing disease and forms the backbone of community-directed treatment with ivermectin (CDTI), the WHO strategy targeting elimination in 26 African countries by 2030.

Key messages

220 million at risk, 1.1 million blind

Onchocerciasis has blinded approximately 1.1 million people and left hundreds of thousands more visually impaired. 220 million people in 31 endemic countries remain at risk (WHO).

Ivermectin (Mectizan) — the largest drug donation

Merck's donation of ivermectin (Mectizan) since 1987 — the largest corporate drug donation in history — has enabled community-directed treatment with ivermectin (CDTI) across Africa, saving millions from blindness.

OEPA — elimination achieved in the Americas

The Onchocerciasis Elimination Programme for the Americas (OEPA) achieved WHO-validated elimination of onchocerciasis as a public health problem in Colombia (2013), Ecuador (2014), Mexico (2015) and Guatemala (2016) — demonstrating that elimination is achievable.

Elimination in Africa by 2030

WHO's NTD Roadmap targets elimination of onchocerciasis as a public health problem in 12 African countries and interruption of transmission in 6 by 2030. Moxidectin (a new drug) may enable faster elimination.

Skin disease burden

Beyond blindness, onchocerciasis causes severe, debilitating skin disease — intense itching (pruritus), skin depigmentation (leopard skin), lichenification (lizard skin) and premature ageing — causing profound suffering and stigma.

Black fly vector control

The Onchocerciasis Control Programme (OCP, 1974-2002) in West Africa used aerial larviciding of Simulium black fly breeding sites along rivers — the first successful large-scale NTD control programme, preventing 600,000 cases of blindness.

Key statistics

220M

people at risk in 31 countries

WHO

1.1M

people blinded by onchocerciasis

WHO

countries in Americas achieved elimination

WHO OEPA

287M+

ivermectin doses distributed/year (peak)

WHO/APOC

2030

WHO elimination target for 12 African countries

WHO NTD Roadmap

1987

year Merck began Mectizan donation

Merck/WHO

People receiving ivermectin for onchocerciasis annually (millions) — WHO/APOC

Source: WHO African Programme for Onchocerciasis Control. Coverage expanded dramatically 2000-2015.

Glossary of key terms

Onchocerca volvulus
WHOA filarial nematode — the causative agent of onchocerciasis. Female worms (up to 50cm long) live in subcutaneous nodules for 15 years, releasing millions of microfilariae that migrate to the skin and eyes, causing the pathological manifestations of disease.

Simulium black fly
WHOThe vector of O. volvulus — a small black fly (Simulium damnosum in Africa) breeding in fast-flowing, oxygenated rivers. Blood-feeding females ingest microfilariae from infected humans; larvae develop in the fly and are transmitted to new hosts during subsequent blood meals.

CDTI (Community-directed treatment with ivermectin)
WHOThe WHO strategy for onchocerciasis control — communities themselves take responsibility for distributing ivermectin annually to all eligible members. Highly effective, sustainable, and empowers communities. Annual treatment kills microfilariae and prevents blindness.

Moxidectin
FDA/WHOA next-generation macrocyclic lactone — approved by FDA in 2018 for onchocerciasis. Single dose reduces skin microfilarial density more profoundly than ivermectin and for a longer period — potentially enabling less frequent treatment and faster elimination.

Sowda
WHO/ClinicalA severe manifestation of onchocerciasis — hyperreactive form predominantly seen in Yemen and Sudan — causing intense localised inflammation, dark skin thickening and severe lymphadenopathy, primarily affecting one limb.

Onchocercal nodule (onchocercoma)
WHOSubcutaneous nodules (pea-sized to marble-sized) containing coiled adult O. volvulus worms — typically over bony prominences (hips, ribs, knees, head). Nodulectomy (surgical removal) reduces microfilarial production.

Latest GMJ coverage

Articles will appear here as the archive grows.

Onchocerciasis (River Blindness)

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company